One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Eli Lilly wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in ...

Obesity is more than just a diet and exercise issue; it's deeply intertwined with psychological and social factors. Experts ...

Experts reveal how to navigate psychological barriers to achieve healthier eating and exercise habits for weight loss.

R Madhavan shared a video on X, talking about obesity. He praised PM Modi for raising awareness and encouraged small, healthy ...

In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen ...

As obesity rates rise across the U.S., a new study from UnitedHealthcare and the Health Action Council examines the financial ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Many patients with overweight or obesity discontinue GLP-1 receptor agonist therapy within 1 year, with higher discontinuation rates seen for those without type 2 diabetes.

Children with overweight and obesity experienced notable improvements in health outcomes after participating in a lifestyle ...

HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...